The USPTO has processed the renewal for the trademark 'ECTODOL', identified by TM99273970. This renewal pertains to a range of pharmaceutical products, including those for ophthalmological use, otorhinolaryngological preparations, respiratory diseases, dermatological conditions, and allergic rhinitis. The renewal is officially effective until March 22, 2026.

This action represents a routine administrative update for the trademark holder. No new compliance obligations are imposed on other entities. The filing date for the renewal application was July 9, 2025. Compliance officers should note this renewal for inventory and intellectual property management purposes, but no immediate action is required.